<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222286</url>
  </required_header>
  <id_info>
    <org_study_id>IPH2101-203</org_study_id>
    <nct_id>NCT01222286</nct_id>
    <nct_alias>NCT01960959</nct_alias>
  </id_info>
  <brief_title>Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma</brief_title>
  <acronym>KIRMONO</acronym>
  <official_title>Multicenter Phase II Study on the Anti-tumor Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Fully Human Monoclonal Anti KIR Antibody, in Patients With Smoldering Multiple Myeloma (KIRMONO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of
      two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized Phase II, open label, multi-centre study, with two independent arms.

      Patients receive 6 injections of IPH2101, at the dose of 0.2 mg/kg or 2 mg/kg (according to
      their randomization) administered over one hour infusion at four weeks intervals.

      A patient whose disease achieves at least a minimal response to study treatment at any time
      during the initial period of 6 cycles can be treated with an additional period of treatment
      of 6 cycles.

      Patients are followed 6 months after treatment completion or until a KIR occupancy level &lt;
      30% (i.e if the time required for KIR desaturation was &gt; 6 months), whichever is longer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Patients Achieving an Objective Response</measure>
    <time_frame>from start to end of study (14 months)</time_frame>
    <description>The primary end point is the rate of patients achieving an objective response (defined according to the International Myeloma Working Group uniform response criteria), including minimal response, (as derived from the European Society for Blood and Marrow Transplantation criteria), achieved at any time until end of study and confirmed on two consecutive assessments at 4 weeks interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>Adverse events collected from screening visit (date of signature of Inform Consent Form) up to the End of Study, up to 14 months</time_frame>
    <description>adverse events, physical examination and biological changes during the whole clinical trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of IPH2101</measure>
    <time_frame>from start to end of study (14 months)</time_frame>
    <description>biological activity of IPH2101 on KIR occupancy at End of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Anti-tumor Activity</measure>
    <time_frame>from start to end of study (14 months)</time_frame>
    <description>any change of M-protein in serum occurring during the study (&gt;25 percentage increase in level of serum M-protein)
progression to active Multiple Myeloma
Definition of active Multiple Myeloma: Evidence of progression based on the IMWG criteria for progressive disease in myeloma and any one or more of the following felt related to the underlying clonal plasma cell proliferative disorder :
Development of new soft tissue plasmacytomas or bone lesions
Hypercalcemia (&gt; 11mg/100ml)
Decrease in hemoglobin of &gt; 2g/100ml
Rise in serum creatinine by 2 mg/100ml or more</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Smoldering Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>IPH2101 0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPH2101 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPH2101</intervention_name>
    <description>0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
    <arm_group_label>IPH2101 0.2 mg/kg</arm_group_label>
    <arm_group_label>IPH2101 2 mg/kg</arm_group_label>
    <other_name>a human monoclonal anti-KIR antibody (1-7F9)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. SMM of any risk level according to a definition derived of the International Myeloma
             Working Group definition ( Br J Haematol 2003; 121: 749) : Serum M protein ≥ 3 g/dl ,
             AND/OR Bone Marrow plasma cells ≥ 10 % with no evidence of end-organ damage (CRAB)

               -  (C)Absence of hypercalcemia : Ca &lt; 10.5 mg/dl

               -  (R)Absence of renal failure : creatinine &lt; 2mg/dl (177 μmol/l) or calculated
                  creatinine clearance(according to MDRD) &gt; 50 ml/min

               -  (A)Absence of anemia : Hb &gt; 11 g/dl

               -  (B)Absence of lytic bone lesion on standard skeletal survey (MRI could be used if
                  clinically indicated)

          2. Measurable disease defined as a disease with a serum M protein ≥ 1 g/dl

          3. No evidence of fatigue, recurrent infections or any clinical suspicion of MM

          4. Diagnosis of SMM confirmed on two consecutive assessments (ie fluctuation under 25% of
             serum protein level) performed with at least a 4 week interval.

          5. Age &gt; 18 years or &lt; 75 years

          6. ECOG performance status of 0 or 1

          7. Male or female patient who accepts and is able to use recognised effective
             contraception (oral contraceptives, IUCD, barrier method of contraception in
             conjunction with spermicidal jelly) throughout the study when relevant

          8. Informed consent signed by the patient

        Exclusion Criteria:

          1. Previous treatment having a proven or potential impact on myelomatous cells
             proliferation or survival (including IMiDs or proteasome inhibitors, conventional
             chemotherapies within the last 5 years, steroids within the last month prior to
             enrolment). Previous bisphosphonates started less than 3 months prior to enrolment.

          2. Use of any investigational agent within the last 3 months

          3. Clinical laboratory values at screening

               -  Platelet &lt; 75 x 10^9 /l

               -  ANC &lt; 1.5 x 10^9 /l

               -  Bilirubin levels &gt;1.5 ULN ; ALT and AST &gt; 3 ULN (grade 1 NCI)

          4. Primary or associated amyloidosis

          5. Abnormal cardiac status with any of the following

               1. NYHA stage III or IV congestive heart failure

               2. myocardial infarction within the previous 6 months

               3. symptomatic cardiac arrhythmia requiring treatment or persisting despite
                  appropriate treatment

          6. Current active infectious disease or positive serology for HIV, HCV or positive Hbs
             Antigen

          7. History of or current auto-immune disease

          8. History of other active malignancy within the past five years (apart from basal cell
             carcinoma of the skin, or in situ cervix carcinoma).

          9. Serious concurrent uncontrolled medical disorder

         10. History of allograft or solid organ transplantation

         11. Pregnant or lactating women

         12. Any condition potentially hampering compliance with the study protocol and follow-up
             schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikhil Munshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute- Medical Oncology- Boston MA-USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <results_first_submitted>November 7, 2013</results_first_submitted>
  <results_first_submitted_qc>April 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2014</results_first_posted>
  <last_update_submitted>April 11, 2014</last_update_submitted>
  <last_update_submitted_qc>April 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoldering Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 44 patients screened, 14 subjects were not randomized, 12 of whom were screen failures, 30 patients randomized.</recruitment_details>
      <pre_assignment_details>All patients enrolled were screened in order to verify the inclusion/exclusion criteria. All patients enrolled (30 patients) were analyzed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IPH2101 0.2 mg/kg</title>
          <description>0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
        </group>
        <group group_id="P2">
          <title>IPH2101 2 mg/kg</title>
          <description>2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IPH2101 0.2 mg/kg</title>
          <description>0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
        </group>
        <group group_id="B2">
          <title>IPH2101 2 mg/kg</title>
          <description>2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="7.62"/>
                    <measurement group_id="B2" value="58.4" spread="13.11"/>
                    <measurement group_id="B3" value="61.2" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Patients Achieving an Objective Response</title>
        <description>The primary end point is the rate of patients achieving an objective response (defined according to the International Myeloma Working Group uniform response criteria), including minimal response, (as derived from the European Society for Blood and Marrow Transplantation criteria), achieved at any time until end of study and confirmed on two consecutive assessments at 4 weeks interval.</description>
        <time_frame>from start to end of study (14 months)</time_frame>
        <population>The ITT population included all randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>IPH2101 0.2 mg/kg</title>
            <description>0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
          </group>
          <group group_id="O2">
            <title>IPH2101 2 mg/kg</title>
            <description>2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Patients Achieving an Objective Response</title>
          <description>The primary end point is the rate of patients achieving an objective response (defined according to the International Myeloma Working Group uniform response criteria), including minimal response, (as derived from the European Society for Blood and Marrow Transplantation criteria), achieved at any time until end of study and confirmed on two consecutive assessments at 4 weeks interval.</description>
          <population>The ITT population included all randomized subjects.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessment</title>
        <description>adverse events, physical examination and biological changes during the whole clinical trial.</description>
        <time_frame>Adverse events collected from screening visit (date of signature of Inform Consent Form) up to the End of Study, up to 14 months</time_frame>
        <population>The safety population included all subjects who received at least 1 dose of IPH2101</population>
        <group_list>
          <group group_id="O1">
            <title>IPH2101 0.2 mg/kg</title>
            <description>0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
          </group>
          <group group_id="O2">
            <title>IPH2101 2 mg/kg</title>
            <description>2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessment</title>
          <description>adverse events, physical examination and biological changes during the whole clinical trial.</description>
          <population>The safety population included all subjects who received at least 1 dose of IPH2101</population>
          <units>Patients with any AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics of IPH2101</title>
        <description>biological activity of IPH2101 on KIR occupancy at End of Treatment</description>
        <time_frame>from start to end of study (14 months)</time_frame>
        <population>all subjects who received at least 1 dose of IPH2101</population>
        <group_list>
          <group group_id="O1">
            <title>IPH2101 0.2 mg/kg</title>
            <description>0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
          </group>
          <group group_id="O2">
            <title>IPH2101 2 mg/kg</title>
            <description>2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics of IPH2101</title>
          <description>biological activity of IPH2101 on KIR occupancy at End of Treatment</description>
          <population>all subjects who received at least 1 dose of IPH2101</population>
          <units>% of occupancy of killer like receptor</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" lower_limit="46" upper_limit="98"/>
                    <measurement group_id="O2" value="92" lower_limit="80" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Anti-tumor Activity</title>
        <description>any change of M-protein in serum occurring during the study (&gt;25 percentage increase in level of serum M-protein)
progression to active Multiple Myeloma
Definition of active Multiple Myeloma: Evidence of progression based on the IMWG criteria for progressive disease in myeloma and any one or more of the following felt related to the underlying clonal plasma cell proliferative disorder :
Development of new soft tissue plasmacytomas or bone lesions
Hypercalcemia (&gt; 11mg/100ml)
Decrease in hemoglobin of &gt; 2g/100ml
Rise in serum creatinine by 2 mg/100ml or more</description>
        <time_frame>from start to end of study (14 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IPH2101 0.2 mg/kg</title>
            <description>0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
          </group>
          <group group_id="O2">
            <title>IPH2101 2 mg/kg</title>
            <description>2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Anti-tumor Activity</title>
          <description>any change of M-protein in serum occurring during the study (&gt;25 percentage increase in level of serum M-protein)
progression to active Multiple Myeloma
Definition of active Multiple Myeloma: Evidence of progression based on the IMWG criteria for progressive disease in myeloma and any one or more of the following felt related to the underlying clonal plasma cell proliferative disorder :
Development of new soft tissue plasmacytomas or bone lesions
Hypercalcemia (&gt; 11mg/100ml)
Decrease in hemoglobin of &gt; 2g/100ml
Rise in serum creatinine by 2 mg/100ml or more</description>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>serum M-protein progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression to active Multiple Myeloma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events related to Study Drug, collected from screening visit (date of signature of Inform Consent Form) up to the End of Study, up to 14 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IPH2101 0.2 mg/kg</title>
          <description>0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
        </group>
        <group group_id="E2">
          <title>IPH2101 2 mg/kg</title>
          <description>2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>This event was assessed as possibly related to study treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <description>This event was assessed as unlikely related to study treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Edema Peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>seasonal allergy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>white blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Renaud Buffet</name_or_title>
      <organization>Innate Pharma</organization>
      <phone>33 4 30 30 30 32</phone>
      <email>renaud.buffet@innate-pharma.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

